Us Congress 2025-2026 Regular Session

House Ways and Means Committee Bills & Legislation (Page 7)

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB405

Introduced
1/15/25  
Keep Every Extra Penny Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB383

Introduced
1/14/25  
End Oil and Gas Tax Subsidies Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB402

Introduced
1/14/25  
Debt Explanation Before Taxwriters Act or the DEBT Act This bill requires the Secretary of the Treasury to appear before the House Ways and Means Committee and the Senate Finance Committee before the federal debt limit is reached or extraordinary measures are taken to prevent the United States from defaulting on its obligations. The term extraordinary measures generally refers to a series of actions that the Department of the Treasury may implement to allow the United States to borrow additional funds without exceeding the debt limit. The measures generally include suspensions or delays of debt sales and suspensions or redemptions of investments in certain government funds. The bill requires the Secretary of the Treasury to appear before the committees to provide a detailed explanation of (1) the extraordinary measures that Treasury will take and the administrative costs of taking the measures, and (2) any reversal of such measures and any other changes in the funding of federal government obligations.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB379

Introduced
1/14/25  
Healthcare Freedom and Choice ActThis bill nullifies a rule regarding short-term, limited-duration health insurance plans. The rule was promulgated by the Internal Revenue Service, Employee Benefits Security Administration, and Department of Health and Human Services; is titled Short-Term, Limited-Duration Insurance and Independent, Noncoordinated Excepted Benefits Coverage; and was published April 3, 2024.Short-term, limited-duration health insurance plans are plans that may only offer coverage for a limited amount of time and are exempt from the market requirements of the Patient Protection and Affordable Care Act (e.g., coverage of individuals with preexisting conditions).The rule limits the length of the initial contract period for such a plan to no more than three months and, taking into account any renewals or extensions, the maximum coverage period to no more than four months. The rule also includes within the maximum renewal period limitation a new plan sold by the same issuer, or any issuer that is a member of the same controlled group, to the same policyholder within a 12-month period.Regulations in effect prior to the rule this bill nullifies permitted short-term, limited-duration health insurance plans with an initial contract period of fewer than 12 months and a maximum coverage period of up to 36 months, including renewals and extensions.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB464

Introduced
1/15/25  
Skills Investment Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB399

Introduced
1/14/25  
To permanently extend the American Samoa economic development tax credit.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB919

Introduced
2/4/25  
Refer
2/4/25  
Chronic Disease Flexible Coverage ActThis bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to includeangiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;anti-resorptive therapy for individuals with osteoporosis or osteopenia;beta-blockers for individuals with congestive heart failure or coronary artery disease;blood pressure monitors for individuals with hypertension;inhaled corticosteroids and peak flow meters for individuals with asthma;insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;international normalized ratio testing for individuals with liver disease or bleeding disorders;low-density lipoprotein testing for individuals with heart disease;statins for individuals with heart disease or diabetes; andselective serotonin reuptake inhibitors for individuals with depression. The bill provides statutory authority for the IRS's guidance. 
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB963

Introduced
2/4/25  
Protecting Social Security Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB953

Introduced
2/4/25  
United States Trade Leadership in the Indo-Pacific Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB950

Introduced
2/4/25  
Saving Seniors Money on Prescriptions ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB930

Introduced
2/4/25  
Stop the Wait Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB990

Introduced
2/5/25  
SAFE Act Simplify Automatic Filing Extensions Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1006

Introduced
2/5/25  
Higher Education Accountability Tax Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB996

Introduced
2/5/25  
Paid Family and Medical Leave Tax Credit Extension and Enhancement Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1020

Introduced
2/5/25  
BOOST Act Broadening Online Opportunities through Simple Technologies Act